About Theravance Biopharma, Inc.

Theravance Biopharma, Inc. operates as a biopharmaceutical company. It focuses on the discovery, research, development, and commercialization of organ-selective medicines. Its products include telavancin under the VIBATIV brand, revefenacin under the TD 4208 brand, and neprilysin. The company was founded in July 2013 and is headquartered in George Town, Cayman Islands.

At the moment the company generates 77M USD in revenues.

On its last earning announcement, the company reported a loss of -4.59$ per share.

The book value per share is -3.22$

Theravance Biopharma, Inc. website

Create a solid portfolio with TBPH

Add TBPH to your portfolio and optimize it!


Revenue USD Gross Margin Operating Income Operating Margin Net Income Earnings Per Share Dividends Payout Ratio Shares Book Value Per Share Operating Cash Flow Cap Spending Free Cash Flow
77M 100.00% -280M -365.20% -270M -4.59 - - 59M -3.22 -217M -5M -222M